Rethinking Bipolar Depression
neuroscienceCME Multimedia SnackPremiere Date: Friday, January 15, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, January 15, 2017
Note: Credit Is No Longer Available
|Charles B. Nemeroff, MD, PhD
Professor of Psychiatry
Director, Institute for Early Life Adversity Research
University of Texas Dell Medical School
Professor and Chair Emeritus
Department of Psychiatry & Behavioral Sciences
University of Miami Miller School of Medicine
|Joseph R. Calabrese, MD
Bipolar Disorders Research Chair and Professor of Psychiatry
Case Western Reserve University School of Medicine
Director, Mood Disorders Program
University Hospitals Case Medical Center
|Mark A. Frye, MD
Professor and Chair, Department of Psychiatry and Psychology
Stephen & Shelly Jackson Family Professorship in Individualized Medicine
Director, Mayo Clinic Depression Center
Bipolar disorder is a frequent and clinically complex psychiatric disorder. Patients with bipolar disorder are exceptionally challenging to manage because of the dynamic, chronic, and fluctuating nature of their disease. The manic presentation of bipolar disorder in adults has received more attention, and treatment options are numerous while the depressive symptoms continue to be misdiagnosed and at present, there are only three FDA-approved treatments for bipolar depression. The use of screening tools in both psychiatry and primary care are underutilized and can assist in diagnosing bipolar depression and monitoring symptoms over time.1
Newer pharmacological agents used to treat the various clinical presentations of bipolar disorder generally offer efficacy with an improved side effect profile over the older second-generation antipsychotics. Clinicians need to keep up-to-date on the pharmacological profiles and safety and efficacy data on all of the recent agents for bipolar disorder.
In this neuroscienceCME Snack, the faculty will analyze and review treatment options for bipolar depression to offer clinicians the optimal, real-world context needed to combine the latest science with best practice to improve outcomes in patients with bipolar depression.
- McIntyre RS, Correll C. Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. Bipolar Disord. 2014;16(5):451-454. PMID: 25090934.
At the end of this CE activity, participants should be able to:
- Integrate evidence-based, best-practice options for the pharmacological management of patients with bipolar disorder.
- Implement a treatment plan in collaboration with patients with bipolar depression that differentiates the long-term metabolic impact of treatment choices.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.
Physicians, pharmacists, and other health care professionals with an interest in mood disorders.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-15-004-L01-P (live programs)
0376-0000-16-014-H01-P (recorded programs)
Activity Type: knowledge-based
To complete your activity evaluation and post-test online, and print your certificate or statement of credit immediately (75% pass rate required), please visit
www.CMEOutfitters.com/20081(requires free account activation).
There is no fee for participation in this activity. The estimated time for completion is 90 minutes.
Questions? Please call 877.CME.PROS
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara);Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Clintara; RiverMend Health, LLC; Skyland Trail; and Xhale, Inc. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); and GratitudeAmerica, Inc. He is a stockholder of AbbVie Inc,; Bracket (Clintara); Celgene Corporation; COPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Dr. Nemeroff has patients for method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Calabrese has no disclosures to report.
Dr. Frye has disclosed that he received grant/research support from AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for Medical Education and Research; Myriad Genetics; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Mental Health (NIMH); and Pfizer Inc. He serves as a consultant for Janssen Research & Development, LLC; Mitsubishi Tanabe Pharma Corporation; Myriad Genetics; Neuralstem Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceuticals USA. He received CME/travel support from American Physician Institute and CME Outfitters, LLC. Mayo Clinic has a financial interest in AssureRX and the technology referenced in this publication/presentation.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).